• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer.

作者信息

Zhang Yang, Wang Zi-Xian, Shen Lin, Li Jin, Huang Jing, Su Wei-Guo, Zhang Dong-Sheng, Xu Rui-Hua

机构信息

Department of Clinical Research, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.

Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China.

出版信息

Cancer Commun (Lond). 2023 Jan;43(1):150-153. doi: 10.1002/cac2.12379. Epub 2022 Nov 4.

DOI:10.1002/cac2.12379
PMID:36331272
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9859731/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cba8/9859731/24c5264507ab/CAC2-43-150-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cba8/9859731/24c5264507ab/CAC2-43-150-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cba8/9859731/24c5264507ab/CAC2-43-150-g001.jpg

相似文献

1
A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer.呋喹替尼联合紫杉醇作为晚期胃癌二线治疗的Ib/II期研究。
Cancer Commun (Lond). 2023 Jan;43(1):150-153. doi: 10.1002/cac2.12379. Epub 2022 Nov 4.
2
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.呋喹替尼在既往接受过治疗的转移性结直肠癌患者中的安全性和有效性：一项Ib期研究和一项随机双盲II期研究。
J Hematol Oncol. 2017 Jan 19;10(1):22. doi: 10.1186/s13045-016-0384-9.
3
Paclitaxel chemotherapy for the treatment of gastric cancer.紫杉醇化疗用于治疗胃癌。
Gastric Cancer. 2009;12(2):69-78. doi: 10.1007/s10120-009-0505-z. Epub 2009 Jun 27.
4
Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.每周紫杉醇联合雷莫芦单抗对比每周nab-紫杉醇联合雷莫芦单抗治疗一线治疗失败的不可切除的晚期或复发性伴腹膜转移的胃癌：由日本西部肿瘤协作组（West Japan Oncology Group）开展的 P-SELECT 试验（WJOG10617G）-一项随机 II 期试验
BMC Cancer. 2020 Jun 12;20(1):548. doi: 10.1186/s12885-020-07047-1.
5
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.拉帕替尼联合紫杉醇对比紫杉醇单药二线治疗亚洲人 HER2 扩增型晚期胃癌：TyTAN--一项随机、III 期研究。
J Clin Oncol. 2014 Jul 1;32(19):2039-49. doi: 10.1200/JCO.2013.53.6136. Epub 2014 May 27.
6
[A case of advanced gastric cancer effectively treated with paclitaxel/S-1 as neoadjuvant chemotherapy].[一例以紫杉醇/S-1作为新辅助化疗有效治疗的晚期胃癌病例]
Gan To Kagaku Ryoho. 2009 Apr;36(4):647-50.
7
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.随机、双盲、安慰剂对照、多中心 II 期研究：氟喹替尼在两种先前化疗方案后用于中国晚期非鳞状非小细胞肺癌患者。
J Clin Oncol. 2018 Apr 20;36(12):1207-1217. doi: 10.1200/JCO.2017.76.7145. Epub 2018 Mar 12.
8
[Second-line treatment for metastatic or locally advanced gastric cancer].[转移性或局部晚期胃癌的二线治疗]
Zhonghua Zhong Liu Za Zhi. 2016 Oct 23;38(10):721-724. doi: 10.3760/cma.j.issn.0253-3766.2016.10.001.
9
[Progress in chemotherapy for advanced gastric cancer].[晚期胃癌化疗的进展]
Ai Zheng. 2009 Oct;28(10):1108-13. doi: 10.5732/cjc.008.10560.
10
Phase II study of weekly paclitaxel following fixed three cycles of S-1-based chemotherapy for advanced gastric cancer.在以S-1为基础的化疗进行固定三个周期后，每周使用紫杉醇治疗晚期胃癌的II期研究。
Hepatogastroenterology. 2011 Mar-Apr;58(106):652-8.

引用本文的文献

1
Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial.呋喹替尼和信迪利单抗联合SOX作为局部可切除的晚期胃/胃食管交界腺癌围手术期治疗：一项前瞻性、单臂、II期临床试验的研究方案
Front Immunol. 2025 Jul 29;16:1638316. doi: 10.3389/fimmu.2025.1638316. eCollection 2025.
2
Clinical benefit of continuation of PD-1 inhibitors after progression on first-line chemoimmunotherapy in metastatic gastric cancer and biomarker exploration.转移性胃癌一线化疗免疫治疗进展后继续使用PD-1抑制剂的临床获益及生物标志物探索
BMC Cancer. 2025 May 24;25(1):935. doi: 10.1186/s12885-025-14286-7.
3

本文引用的文献

1
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.雷莫西尤单抗联合或不联合紫杉醇每周给药作为晚期胃或胃食管交界腺癌二线治疗的疗效和安全性（RAINBOW-亚洲）：一项随机、多中心、双盲、3期试验
Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1015-1024. doi: 10.1016/S2468-1253(21)00313-7. Epub 2021 Oct 7.
2
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.一线纳武利尤单抗联合化疗与单纯化疗治疗晚期胃癌、胃食管交界癌和食管腺癌（CheckMate 649）：一项随机、开放标签的3期试验。
Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5.
3
The Adverse Impact of Tyrosine Kinase Inhibitors on Wound Healing and Repair.
酪氨酸激酶抑制剂对伤口愈合和修复的不良影响。
Int Wound J. 2025 Apr;22(4):e70513. doi: 10.1111/iwj.70513.
4
Fruquintinib inhibits the migration and invasion of colorectal cancer cells by modulating epithelial-mesenchymal transition via TGF-β/Smad signaling pathway.呋喹替尼通过TGF-β/Smad信号通路调节上皮-间质转化，从而抑制结肠癌细胞的迁移和侵袭。
Front Oncol. 2025 Mar 11;15:1503133. doi: 10.3389/fonc.2025.1503133. eCollection 2025.
5
Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview.呋喹替尼在结直肠癌中的临床进展：综述
Pharmaceuticals (Basel). 2025 Feb 19;18(2):280. doi: 10.3390/ph18020280.
6
Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns.胃食管肿瘤分子生物标志物的现状及共表达模式的潜在策略
Cancers (Basel). 2025 Jan 21;17(3):340. doi: 10.3390/cancers17030340.
7
Clinical research progress of fruquintinib in the treatment of malignant tumors.呋喹替尼治疗恶性肿瘤的临床研究进展
Invest New Drugs. 2024 Dec;42(6):612-622. doi: 10.1007/s10637-024-01476-6. Epub 2024 Oct 1.
8
Efficacy and Safety of Fruquintinib-Based Treatment in Patients with Refractory Bone and Soft Tissue Sarcoma after Developing Resistance to Several TKIs: A Multicenter Retrospective Study.基于 Fruquintinib 的治疗在对几种 TKI 产生耐药性后难治性骨和软组织肉瘤患者中的疗效和安全性：一项多中心回顾性研究。
Orthop Surg. 2024 Oct;16(10):2380-2390. doi: 10.1111/os.14163. Epub 2024 Jul 18.
9
Copper(II) Complexes with Isomeric Morpholine-Substituted 2-Formylpyridine Thiosemicarbazone Hybrids as Potential Anticancer Drugs Inhibiting Both Ribonucleotide Reductase and Tubulin Polymerization: The Morpholine Position Matters.具有异构吗啉取代的2-甲酰基吡啶硫代半卡巴腙杂化物的铜（II）配合物作为抑制核糖核苷酸还原酶和微管蛋白聚合的潜在抗癌药物：吗啉位置的重要性。
J Med Chem. 2024 Jun 13;67(11):9069-9090. doi: 10.1021/acs.jmedchem.4c00259. Epub 2024 May 21.
10
PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.PD-1 抑制剂联合白蛋白紫杉醇和安罗替尼二线治疗转移性胃癌患者的单中心、单臂、Ⅱ期研究。
Invest New Drugs. 2024 Apr;42(2):171-178. doi: 10.1007/s10637-024-01425-3. Epub 2024 Feb 12.
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.呋喹替尼对比安慰剂用于既往接受过治疗的转移性结直肠癌患者的总生存期：FRESCO 随机临床试验。
JAMA. 2018 Jun 26;319(24):2486-2496. doi: 10.1001/jama.2018.7855.
4
A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.一项关于呋喹替尼（一种新型血管内皮生长因子受体-1、-2和-3酪氨酸激酶选择性抑制剂）在中国晚期实体瘤患者中的安全性和药代动力学的I期研究。
Cancer Chemother Pharmacol. 2016 Aug;78(2):259-69. doi: 10.1007/s00280-016-3069-8. Epub 2016 Jun 14.
5
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.雷莫芦单抗联合紫杉醇对比安慰剂联合紫杉醇治疗既往治疗的晚期胃或胃食管结合部腺癌患者（RAINBOW）：一项双盲、随机、III 期临床试验。
Lancet Oncol. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17.
6
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.随机、开放标签、III 期研究比较了伊立替康与紫杉醇在氟嘧啶加铂类化疗失败后无严重腹膜转移的晚期胃癌患者中的疗效：WJOG4007 试验。
J Clin Oncol. 2013 Dec 10;31(35):4438-44. doi: 10.1200/JCO.2012.48.5805. Epub 2013 Nov 4.
7
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.多中心 II 期研究奥沙利铂和索拉非尼治疗顺铂和氟嘧啶治疗失败的晚期胃腺癌。GEMCAD 研究。
Invest New Drugs. 2013 Dec;31(6):1573-9. doi: 10.1007/s10637-013-0020-2.
8
Phase II study of sunitinib as second-line treatment for advanced gastric cancer.舒尼替尼二线治疗晚期胃癌的 II 期研究。
Invest New Drugs. 2011 Dec;29(6):1449-58. doi: 10.1007/s10637-010-9438-y. Epub 2010 May 12.
9
Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.白蛋白结合型紫杉醇、卡铂和贝伐珠单抗联合治疗一线晚期非鳞状非小细胞肺癌的 II 期临床试验。
J Thorac Oncol. 2009 Dec;4(12):1537-43. doi: 10.1097/JTO.0b013e3181c0a2f4.
10
Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer.每周使用紫杉醇和贝伐单抗治疗复发性卵巢癌可实现持续无进展生存。
Gynecol Oncol. 2009 Dec;115(3):396-400. doi: 10.1016/j.ygyno.2009.08.032. Epub 2009 Oct 4.